251 related articles for article (PubMed ID: 23716996)
1. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma.
Chen K; Zhang H; Zhang LN; Ju SQ; Qi J; Huang DF; Li F; Wei Q; Zhang J
World J Gastroenterol; 2013 May; 19(20):3143-9. PubMed ID: 23716996
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma.
Mossad NA; Mahmoud EH; Osman EA; Mahmoud SH; Shousha HI
Tumour Biol; 2014 Nov; 35(11):11559-64. PubMed ID: 25129443
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma.
Yan L; Chen Y; Zhou J; Zhao H; Zhang H; Wang G
Int J Infect Dis; 2018 Feb; 67():92-97. PubMed ID: 29229500
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma.
Xing H; Qiu H; Ding X; Han J; Li Z; Wu H; Yan C; Li H; Han R; Zhang H; Li C; Wang M; Wu M; Shen F; Zheng Y; Yang T
Biomark Med; 2019 May; 13(7):545-555. PubMed ID: 31140827
[No Abstract] [Full Text] [Related]
6. Enhanced detection of hepatocellular carcinoma.
el-Houseini ME; Mohammed MS; Elshemey WM; Hussein TD; Desouky OS; Elsayed AA
Cancer Control; 2005 Oct; 12(4):248-53. PubMed ID: 16258497
[TBL] [Abstract][Full Text] [Related]
7. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand.
Tangkijvanich P; Tosukhowong P; Bunyongyod P; Lertmaharit S; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
Southeast Asian J Trop Med Public Health; 1999 Mar; 30(1):110-4. PubMed ID: 10695798
[TBL] [Abstract][Full Text] [Related]
8. Serological biomarkers of hepatocellular carcinoma in Egyptian patients.
El-Tayeh SF; Hussein TD; El-Houseini ME; Amer MA; El-Sherbini M; Elshemey WM
Dis Markers; 2012; 32(4):255-63. PubMed ID: 22430192
[TBL] [Abstract][Full Text] [Related]
9. Serum midkine is a more sensitive predictor for hepatocellular carcinoma than Dickkopf-1 and alpha-L-fucosidase in cirrhotic HCV patients.
El-Shayeb AF; El-Habachi NM; Mansour AR; Zaghloul MS
Medicine (Baltimore); 2021 Apr; 100(17):e25112. PubMed ID: 33907088
[TBL] [Abstract][Full Text] [Related]
10. Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.
Zhang HJ; Yao DF; Yao M; Huang H; Wu W; Yan MJ; Yan XD; Chen J
World J Gastroenterol; 2012 Nov; 18(41):5897-904. PubMed ID: 23139605
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis.
Gan Y; Liang Q; Song X
Tumour Biol; 2014 May; 35(5):3953-60. PubMed ID: 24395655
[TBL] [Abstract][Full Text] [Related]
12. [A preliminary study on serum alpha-L-fucosidase assay in the diagnosis of hepatocellular carcinoma].
Shen W; Shen DM
Zhonghua Nei Ke Za Zhi; 1989 Jul; 28(7):397-9, 442-3. PubMed ID: 2480210
[TBL] [Abstract][Full Text] [Related]
13. Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma.
Fawzy Montaser M; Amin Sakr M; Omar Khalifa M
Arab J Gastroenterol; 2012 Mar; 13(1):9-13. PubMed ID: 22560818
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma.
Zhang SY; Lin BD; Li BR
FEBS Open Bio; 2015; 5():240-4. PubMed ID: 25870783
[TBL] [Abstract][Full Text] [Related]
16. Serological tumor markers of hepatocellular carcinoma: a meta-analysis.
Hussein TD
Int J Biol Markers; 2015 Feb; 30(1):e32-42. PubMed ID: 25450646
[TBL] [Abstract][Full Text] [Related]
17. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
18. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
[TBL] [Abstract][Full Text] [Related]
19. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
[TBL] [Abstract][Full Text] [Related]
20. Combined analysis of serum γ-glutamyl transferase isoenzyme II, α-L-fucosidase and α-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma.
Zhu J; Jiang F; Ni HB; Xiao MB; Chen BY; Ni WK; Lu CH; Ni RZ
Exp Ther Med; 2013 Jan; 5(1):89-94. PubMed ID: 23251247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
